Please check your internet connection and try again.
# Arsil-DX
## Overview
Arsil-DX is a proprietary formulation primarily marketed in specific international markets (e.g., SE Asia) as a combination product. It typically contains **Dextromethorphan HBr** (antitussive) and **Chlorpheniramine Maleate** (first-generation antihistamine). Note: Always verify the specific brand formulation, as "Arsil" branding can refer to different regional products.
## Primary Indications
Symptomatic relief of dry, non-productive cough associated with the common cold, upper respiratory allergies, or hay fever.
## Adult Dosing
* **Standard dose:** 1–2 tablets (or 10 mL syrup) every 6–8 hours as needed.
* **Maximum daily dose:** Do not exceed 4 doses (or max labeling instructions) in 24 hours.
## Pediatric Dosing
* **Children 6–12 years:** 0.5–1 tablet (or 5 mL) every 6–8 hours.
* **Children <6 years:** Generally not recommended without direct pediatric oversight due to potential for respiratory depression/sedation. Consult local pharmacy guidelines.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Use with caution; no specific standardized adjustments, but lower frequency is advised due to risk of accumulation of chlorpheniramine.
* **Elderly:** Use lowest effective dose; risk of paradoxical excitation, confusion, and urinary retention.
## Contraindications
* Hypersensitivity to dextromethorphan or chlorpheniramine.
* Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing them (risk of serotonin syndrome).
* Narrow-angle glaucoma, symptomatic prostatic hypertrophy, or bladder neck obstruction.
## Adverse Effects
* **CNS:** Drowsiness, sedation, dizziness.
* **Anticholinergic:** Dry mouth, blurred vision, constipation, urinary retention.
* **GI:** Nausea/vomiting.
* **Respiratory:** Thickening of bronchial secretions (caution in patients with COPD/asthma).
## Key Drug Interactions
* **MAOIs:** Fatal hypertensive crisis and serotonin syndrome.
* **CNS Depressants:** Alcohol, sedatives, or hypnotics (additive CNS depression).
* **SSRIs:** Potential risk of increased serotonergic activity.
## Monitoring
* Monitor for excessive sedation or respiratory depression.
* Assess for relief of cough symptoms.
* Monitor for signs of anticholinergic toxicity (especially in elderly patients).
## Clinical Pearls
* **Sedation:** Advise patients to avoid driving or operating heavy machinery until effect is known.
* **Avoid Alcohol:** Strongly contraindicated due to potentiation of sedative effects.
* **Drug-Drug Check:** Always screen for other OTC products containing antihistamines or dextromethorphan to prevent accidental overdose.
* **Uncertainty:** Because "Arsil-DX" is a regional name, verify the exact milligram strength per dosage unit on the physical packaging; compositions vary by country.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug formulations, local protocols, and regulatory approvals vary significantly by region. Always verify specific dosing and contraindications against the manufacturer's official package insert and current local clinical prescribing guidelines before administration.
